Program: AETERNAVIR™
Subsystem: GoldenCSF-AET™ Chronobiologic Carrier System
Phase Objective: Validate the carrier system under physiological conditions, confirming pharmacokinetic behavior, lymphatic targeting, biodistribution, and chronobiologic performance in vivo.
1. Phase 4 Purpose
Phase 4 establishes whether the in vitro–validated chronobiologic delivery system (Phase 3) translates into:
- Predictable systemic pharmacokinetics (PK)
- Effective lymphatic and immune-tissue targeting
- Controlled temporal separation of payload exposure in vivo
- Acceptable safety and tolerability profile
This phase is mandatory for IND-enabling preclinical development, forming the bridge between formulation validation and human trials
2. Phase 4 Deliverables
Primary Deliverable
Chronobiologic Carrier System — In Vivo PK/BD & Chrono-Validation Report (CCS-IVC-004)
Secondary Outputs
- Full PK profiles (Indevirate™ and Glymorisulfonin™)
- Tissue biodistribution maps (multi-organ + lymphatic)
- Chronobiologic exposure curves (time-aligned)
- Safety and tolerability dataset
- Dose-scaling and exposure modeling dataset
3. Study Design Framework
3.1 Animal Models
Model Type | Purpose |
Rodent (rat/mouse) | Initial PK, biodistribution, tolerability |
Non-human primate (optional, later stage) | Translational PK validation |
3.2 Study Arms
Arm | Description |
A | AETERNAVIR™ with GoldenCSF-AET™ (test) |
B | Non-chronobiologic formulation (control) |
C | Single-payload controls (optional mechanistic arms) |
4. Pharmacokinetic (PK) Evaluation
4.1 Core PK Parameters
Parameter | Objective |
Cmax | Peak exposure control |
Tmax | Temporal alignment validation |
AUC | Overall exposure |
Half-life (t½) | Persistence and dosing interval |
Clearance | Elimination profile |
4.2 Dual-Payload PK Separation
Required Outcome:
Metric | Target |
Indevirate™ Tmax | Early phase (confirm Phase 3) |
Glymorisulfonin™ Tmax | Delayed phase (≥ defined offset) |
Peak overlap | Minimal in vivo overlap |
5. Biodistribution Mapping
5.1 Target Tissues
Tissue/System | Relevance |
Lymph nodes | HIV reservoir targeting |
Gut-associated lymphoid tissue (GALT) | Major viral reservoir |
Spleen | Immune modulation |
Liver | Metabolic clearance |
Plasma | Systemic exposure baseline |
5.2 Measurement Techniques
- LC-MS/MS quantification
- Radiolabeled tracing (if applicable)
- Fluorescent nanoparticle tracking
5.3 Target Outcomes
Parameter | Target |
Lymphatic accumulation | Elevated vs plasma baseline |
Reservoir tissue penetration | Demonstrated presence |
Off-target accumulation | Minimal |
6. Chronobiologic Validation (In Vivo)
6.1 Chrono-Exposure Mapping
Construct In Vivo Chrono-Release Alignment Map (IV-CRAM):
Time Window | Observed Payload Dominance | Validation Goal |
T0–T4 hr | Indevirate™ dominant | Viral suppression window |
T6–T18 hr | Glymorisulfonin™ rising | Reservoir targeting window |
T18+ hr | Sustained immune modulation | Maintenance phase |
6.2 Circadian Interaction Assessment
Evaluate:
- dosing time vs PK variation
- metabolic phase sensitivity
- immune-response timing effects
This aligns with SCF chronotherapeutic and immune-phase synchronization requirements
7. Safety & Tolerability Assessment
7.1 Parameters
Category | Metrics |
Clinical signs | Behavior, weight, survival |
Hematology | CBC, immune markers |
Biochemistry | Liver enzymes, renal function |
Histopathology | Organ integrity |
7.2 Safety Targets
Parameter | Requirement |
Acute toxicity | None or minimal |
Organ toxicity | Within acceptable limits |
Immune overactivation | Controlled / absent |
8. Dose Optimization & Scaling
8.1 Dose Range Finding
- Identify minimum effective dose (MED)
- Identify maximum tolerated dose (MTD)
8.2 PK/PD Modeling
- Exposure-response relationship
- Chronobiologic dose timing optimization
- Projection to human-equivalent dosing
9. SCF Multi-Omic Validation Layer
9.1 Biomarker Panels
Omics Layer | Biomarker Examples |
Immunomics | Cytokine profiles, CD4/CD8 ratios |
Transcriptomics | Immune signaling gene expression |
Metabolomics | Energy metabolism markers |
Viromics | Viral load / reservoir indicators |
9.2 Functional Goals
- Confirm immune reprogramming without dysregulation
- Validate reservoir-targeting signals
- Ensure no systemic inflammatory cascade
10. SCF Synergy Confirmation (In Vivo)
Metric | Expected Outcome |
TSSM | Sustained antiviral pressure + immune modulation |
HSV-F² | Efficient systemic energy utilization |
SV-EQ | Target-specific biodistribution |
MGIS | PK–geometry alignment maintained in vivo |
SPCI | High tolerability |
11. Phase 4 Go/No-Go Criteria
Criterion | Advancement Threshold |
PK separation | Confirmed in vivo |
Chronobiologic alignment | IV-CRAM validated |
Lymphatic targeting | Demonstrated |
Safety | Acceptable profile |
Dose scalability | Defined |
SCF synergy | Maintained in vivo |
Failure triggers:
- return to Phase 2 (material redesign) or Phase 3 (calibration refinement)
12. Phase 4 Formal Output Statement
Phase 4 Result:
GoldenCSF-AET™ is validated as an in vivo functional chronobiologic delivery system, demonstrating:
- controlled dual-payload pharmacokinetics
- effective lymphatic and reservoir tissue targeting
- preserved chronobiologic release sequencing
- and an acceptable preclinical safety profile.
This establishes readiness for IND-enabling toxicology and clinical translation (Phase 5).
MASTER REGISTRY INDEX
SCF-CCS-HIV-AET-P4-004
SCF-CCS-HIV-AET-P3-003
SCF-CCS-HIV-AET-P2-002
SCF-CCS-HIV-AET-P1-001
SCF-CRD-WORKFLOW-0001
SCF-SEF-MD-0001